Cite

HARVARD Citation

    Indini, A. et al. (2021). Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. Lancet oncology. 22 (5), pp. 573-575. [Online]. 
  
Back to record